Protokinetix Inc. News! 200 % Chance!
Seite 2 von 2 Neuester Beitrag: 03.05.05 12:49 | ||||
| Eröffnet am: | 23.02.05 16:09 | von: Calibra21 | Anzahl Beiträge: | 36 |
| Neuester Beitrag: | 03.05.05 12:49 | von: istvan4 | Leser gesamt: | 4.838 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < 1 | > | ||||
The Company
ProtoKinetix, Inc. (OTCBB: PKTX) is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies. The company is focused on a new generation of monoclonal antibodies termed "Super-antibodies." These antibodies are engineered to provide higher potency and resiliency resulting in vastly enhanced therapeutic impact. ProtoKinetix is using this technology to create therapeutic antibodies to help in the treatment of cancer.
ProtoKinetix has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This enables the company to complete rapid and meaningful research at a fraction of the traditional cost.
As a result of this talented network, ProtoKinetix has been able to acquire technology to provide the rapid development of products to generate early cash flow. Dr. Jean-Charles Quirion, a member of the ProtoKinetix Scientific Advisory Board, working with the University of Rouen (France) has been able to synthesize the AFGP (antifreeze glycoprotein) molecule in a stable form. AFGP is a natural compound which enables fish, reptiles, plants and insects to survive freezing temperatures. Using a patented process, Dr. Quirion was able to replicate the natural AFGP molecule in a stable form that keeps the same biological functions as the natural molecule. AFGP is a valuable molecule with many potential uses. It can enable low temperature preservation of cells, tissue and organs. This would facilitate hypothermic storage of blood platelets and human organs that are intended for transplantation.
The ability of AFGPs to preserve blood platelets for an extended period of time has the potential to make it a very valuable product. The extension of platelet shelf life over the existing 4 days will dramatically enhance the ability of the world's blood banks to store and subsequently deliver the vitally needed blood platelets. Blood platelets are the critical component in the prevention of hemorrhaging and are used in all forms of surgery and the treatment of trauma. In addition to the preservation of blood platelets, which represents a multi billion dollar industry, the characteristics of AFGPs will enable the extension of shelf life of:
cell lines for biomedical research
biologically based vaccines
donor organs
cell cultures for testing and research.
ProtoKinetix has the worldwide exclusive license to produce and market synthetic AFGPs.
Corporate Overview
Finding a cure for cancer has been a preoccupation of the medical research sector for several decades, and in recent years, significant progress has been made largely thanks to a number of approaches involving molecular engineering.
Recent advances have yet to deliver a cure for cancer, however by zeroing in on tumors with specific antibodies, scientists are having success in at least arresting this deadly disease. They hope to convert cancer from a terminal disease to a chronic disease.
Several companies are involved in the research and development of anti-cancer antibodies. ProtoKinetix has strategically positioned itself in this exciting arena by securing licenses and strategic alliances.
Moreover, ProtoKinetix is now making its own headline news in the field of oncology. This is illustrated by the April 2004 announcement of encouraging preliminary results from the third-party validation trials on receptor alpha fetaprotein (RECAF™) molecules. These trials are being conducted at the Georges Pompidou Hospital in France, which is one of the foremost medical institutions in Europe with one of the most advanced cancer research centres in the world.
Dr. Jean-Marie Dupuy, a ProtoKinetix advisor and a recent appointment to the board of directors, termed the results "very positive," adding that the labelling of the malignant cells was strong and clear, with a distinct delineation between malignant and normal cells. That is a promising development at this early stage, but a closer look at ProtoKinetix and its chosen field will provide a clearer picture of the company's potential.
A quick overview should provide investors with a good indication of the opportunities that the company hopes to exploit.
Simply stated, an antibody is a protein that is created by one’s own body to fight a foreign substance and different antibodies are required to fight each unique germ or other invader. Monoclonal antibodies are mass produced identical antibodies produced in a laboratory. A highly specific antibody will attack only its designated target.
It is because of that trait that monoclonal antibodies are playing an important role in the war against cancer. Conventional pharmaceutical cancer treatments such as chemotherapy are often highly toxic, attacking healthy cells and tissue, as well as the malignant tumors. As monoclonal antibodies target only the specific tumor cells that they were designed to attack, the treatment is relatively non-toxic and results in far fewer undesirable side effects.
As therapeutic drugs, monoclonal antibodies are already responsible for more product approvals and pending approvals in recent years than any other sector of the biotechnology industry. ProtoKinetix’ business strategy centers on the modification of monoclonal antibodies to improve their potency. In turn, this improves their effectiveness in fighting foreign invaders such as cancer cells.
Based on early successes with its validation trials, a key part of ProtoKinetix’s scientific strategy will involve an attempt to create a “super-antibody” that will attach itself to RECAF™ molecules. Alpha fetaprotein is a carbohydrate molecule that is located on the surface of cancer cells. RECAF™ molecules with an attached “super-antibody” would theoretically attach themselves to the cancer cells, while causing little or no harm to non-cancerous cells.
The RECAF™ technology is patented by BioCurex Inc. ProtoKinetix has an exclusive worldwide license to use the RECAF™ receptor in conjunction with the super antibody technology and with the catalytic antibody platform.
Researchers have known about monoclonal antibodies for more than 25 years but much of the current interest in the field has gathered momentum within the past decade. This follows on the heels of the approval by the United States Food and Drug Administration of Rituxan as a “breakthrough blockbuster” cancer treatment in 1997. Since then, Idec and Genentech’s sales of Rituxan have grown exponentially, reaching US $818 million in 2001 and an extraordinary US $1.49 billion in 2003.
The Rituxan success story and the opportunities offered by further developments in monoclonal antibodies have resulted in some high valuations for a variety of biotechnology companies in recent years. It is therefore no surprise that there are now a large number of companies hopping aboard the monoclonal antibody bandwagon. This scenario makes ProtoKinetix’s business plan all the more compelling.
Late last year, ProtoKinetix signed an agreement with Perigene Inc., awarding that company a contract to conduct research into the development of a catalytic antibody against the RECAF™ receptor site. Perigene acquired the rights to what is known as abzyme technology from the University of Compiegne in France. The work is scheduled to begin after the completion of encouraging validation trials being conducted at the George Pompidou Hospital.
The recent positive news from the trials appears to be an important milestone development. The validation trials are designed to confirm the existence of a receptor site that is unique to cancer cells that will bind the molecule alpha fetaprotein. A member of ProtoKinetix’s scientific advisory board, Dr. Ricardo Moro, has demonstrated that the presence of alpha fetaprotein in the human body can be a non-specific indicator of the presence of cancer. Dr. Moro and ProtoKinetix believe that the RECAF™ receptor site exists as a specific receptor site for alpha fetaprotein and the positive early results of the validation trials appears to support that belief.
The development of monoclonal antibodies to the highly specific carbohydrate molecule attached to the RECAF™ protein will allow ProtoKinetix to engineer an antibody that should target and kill malignant cells. Based on the results of the validation trials, ProtoKinetix will generate antibodies to the RECAF™ receptor site and identify those that do not have a tendency to attack healthy cells. This work will be a key part of the arrangement with Perigene.
According to its business plan, ProtoKinetix is responsible for covering the costs of its various contracts and it will retain al of the product rights that flow from the deals, while granting incentive arrangements and royalties to its contractors. Each contract will involve the early-stage product development, which will then be advanced through contract research organizations that have expertise in clinical development.
Dr. Todd, president of ProtoKinetix, has invaluable experience in pharmaceutical drug development. A noteworthy entry on his resume is his participation in mammastatin research and the clinical development of mammastatin from natural sources. A graduate of the University of Calgary, Dr. Todd now practices as a surgeon in British Columbia.
Dr. Dupuy was added to the scientific advisory board of ProtoKinetix late last year, and he was appointed to the company’s board of directors in early April. He was instrumental in arranging the validation trials for the RECAF™ molecules. Dr. Dupuy is engaged as a consultant to several pharmaceutical and biotechnology companies, providing project development, scientific advice and clinical research, as well as clinical trial implementation and regulatory agency assistance.
Prior to his career in the pharmaceutical sector, Dr. Dupuy held several academic positions in both France and Canada. He was head of the Immunology and Virology Research Centre in France through most of the 1970s, and following that, he directed clinical immunology at the Montreal Children's Hospital for eight years. As a director in charge of medical research for ProtoKinetix, Dr. Dupuy will be consulting with major European institutions regarding possible collaboration on a number of potential products.
Dr. Maximilien Arella accepted a position as Chairman of the ProtoKinetix Scientific Advisory Board in September 2003. Dr. Arella is a Professor at the Microbiology and Biotechnology Research Centre, INRS —Institut, Armand-Frappier, University du Quebec. He has extensive international experience in the field of molecular biology and monoclonal antibody development.
Future Outlook
The investment community should take note and begin to understand the multi-billion dollar marketing implications of the development of anticancer “super-antibodies.” ProtoKinetix is well on its way to establishing itself as a significant player in the field of molecular biology for the treatment of cancer.
News Deutschland [ mehr ]
Synthetische AFGPs von ProtoKinetix konserv. rote Blutkörper bei Minustemperatur
24.03.2005 (09:49)
ProtoKinetix, Inc. (FRANKFURT: PKD; OTCBB: PKTX), Vancouver, B.C., 23. März 2005 – Unabhängige Tests mit synthetischen Antifrost Glykoproteinen (AFGPs) von ProtoKinetix, Inc. (News/Board/Kurs/Chart) bestätigen die Konservierung von menschlichen roten Blutkörpern bei Temperaturen von bis zu Minus 15 Grad Celsius. Die in dem Labor ProteoCell Biotechnologies durchgeführten Tests bestätigten die hervorragende Wirkung: Das AFGP Molekül verringerte die Hämolyse-Quote (= Zerstörung von roten Blutkörpern) drastisch. Die Tests bewiesen, dass rote Blutkörper in einer AFGP-Lösung einwandfrei konserviert werden. Achtundneunzig Prozent der roten Blutkörper, die sich in einer AFGP-Lösung befanden, waren nach neun Stunden Kühlung bei Minus 15 Grad Celsius unbeschädigt. Sämtliche roten Blutkörper, die nicht durch synthetische AFGPs geschützt waren, wurden bei gleicher Kühltemperatur zerstört.
Das Antifrost Glycoprotein ist ein natürlicher Stoff, der es Fischen, Reptilien und Insekten ermöglicht, bei Temperaturen unter Null überleben zu können. Alle bisherigen Tests bewiesen, dass die synthetischen AFGP wie die natürlichen AFGP funktionieren. Dr. John Todd, President der ProtoKinetix, erklärt: „Die bewiesene Stabilität und Ungiftigkeit unseres Moleküls sowie dessen Fähigkeit, Zellen zu konservieren, ist eine hervorragende Ausgangsposition für den Markteintritt.“ Weitere Tests werden durchgeführt, um die Konservierung verschiedener Zellen, Gewebe und Organe festzustellen. ProtoKinetix sieht sich in einer ausgezeichneten Ausgangsposition für den Beginn der Vermarktung.
Über ProtoKinetix:
ProtoKinetix Inc. entwickelt Produkte zur Verbesserung der medizinischen Versorgung von Menschen. Das synthetische Antifrost Glykoprotein (AFGP) ist das erste Produkt, das die Gesellschaft in den Markt einführen wird. ProtoKinetix vereint in seinem hervorragenden Netzwerk weltweit führende Wissenschaftler. Mit diesem integrierten wissenschaftlichen Ansatz kombiniert das Unternehmen die Bereiche Physik, Chemie und Molekularbiologie, um eine beschleunigte Produktentwicklung zu erzielen.
Weitere Informationen:
Value Relations GmbH, Sternstr. 15, D-60318 Frankfurt am Main
Birgit Eggersmeier, Tel.: (069) 95 92 46 11, Fax: (069) 95 92 46 20, Email: b.eggersmeier@vrir.de
ProtoKinetix INC
Suite 1500, 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8
Tel.: +1 (604) 687-9887, Fax: +1 (604) 687-6652, Email: info@Protokinetix.com
Weitere Unternehmensmeldungen (ISIN US7437221002)
Diskussionen zu dieser ISIN im Börsenboard
Aktueller Kurs (ISIN US7437221002)
Aktueller Chart (ISIN US7437221002)
Artikel empfehlen Zurück Zurück zur Übersicht